Bombay High Court orders withdrawal of FDA's Cipla Pune license cancellation
The story in brief
The Bombay High Court criticized the Maharashtra FDA for improperly canceling Cipla Pune's drug sale license, ordering the decision to be withdrawn. The FDA had canceled the license for irregularities in packaging, storage, and recall of Reactin Plus Tablets, but the court found the process violated natural justice. The regulator promised to issue a fresh show-cause notice and a reasoned decision after hearing Cipla's response.